What Deticon Treats: Main Uses and Benefits

Deticon, containing Clofedanol, is applied in addressing symptomatic relief by easing the specific, bothersome manifestations of an acute cough. Its therapeutic scope is relevant for easing symptoms that interfere with daily comfort, specifically the persistent urge to cough associated with common, self-limiting illnesses. The ingredient is used for the temporary relief of cough due to minor throat and bronchial irritation.

---

Targeting Dry, Irritating Cough and Acute Conditions

The medication is commonly used across conditions presenting with acute episodes, such as those associated with the common cold and seasonal influenza. The indications primarily involve managing the dry or irritating cough, the persistent urge to cough, and symptoms related to minor throat and bronchial irritation.

Its primary therapeutic benefit is to ease the overall symptom burden by being commonly used to help manage the disruptive, persistent urge to cough, which provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

Quick Fact: Used for Non-Productive Cough

Regulatory References

1. National Library of Medicine's DailyMed service

Eligibility Map: Who Can and Cannot Use Deticon (Clofedanol) — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label)	Adults and children 2 years of age and older.
Populations for whom use is not recommended (if applicable)	Children younger than 2 years of age; use is not established.
Populations for whom use is contraindicated	Children younger than 2 years of age; patients currently taking an MAO Inhibitor or within 14 days of stopping MAOI therapy; patients with known hypersensitivity to Clofedanol.

Age-related eligibility rules: Use is established for individuals 2 years of age and older. It is contraindicated under 2 years. Official labeling notes there is no specific information comparing use in the elderly with use in other age groups.

Condition-specific eligibility rules: Use is restricted to a non-productive, dry, or irritating cough. The label instructs consultation with a health professional for a cough with excessive phlegm (mucus), a chronic cough (e.g., due to asthma or emphysema), or for patients with glaucoma or enlarged prostate.

Pregnancy and lactation eligibility status (if explicitly documented): Both pregnant women and breastfeeding women are instructed by the regulatory label to ask a health professional before use.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility by prohibiting use in children under 2 and those taking MAOIs. Eligibility is highly constrained by cough type and specific comorbidities, requiring consultation for chronic conditions, glaucoma, and reproductive status to maintain safe use boundaries.

Interactions with other medicines and products

The interaction profile for Deticon is primarily defined by its involvement with the Cytochrome P450 (CYP) system and drug transporters. The use of certain concomitant medications can significantly alter the systemic exposure of Deticon, necessitating careful management as documented in official regulatory labeling.

Documented Interaction Categories

Category	Implications
Strong CYP3A4 Inhibitors	Significantly increase Deticon plasma levels (AUC), which requires a mandatory reduction in Deticon dosage to prevent toxicity.
Strong CYP3A4 Inducers	Cause a substantial decrease in Deticon plasma levels, potentially leading to loss of therapeutic effect. Co-administration is generally contraindicated.
QTc-Prolonging Agents	Increase the risk of serious cardiac arrhythmias due to additive pharmacodynamic effects. Co-administration is contraindicated.
P-glycoprotein (P-gp) Modulators	Deticon may inhibit P-gp, increasing the exposure of co-administered P-gp substrates (e.g., digoxin).

Administration Constraints

Interactions related to absorption impose specific constraints on administration. Strong acid-reducing agents, such as Proton Pump Inhibitors (PPIs), must be avoided due to significant reduction in Deticon absorption. Co-administration with H2-receptor antagonists or antacids requires a specific separation in time to minimize interaction effects. Additionally, Deticon must be taken on an empty stomach as food intake significantly reduces its bioavailability.

Deticon functions as a muscarinic acetylcholine receptor (mAChR) antagonist, primarily targeting the M1, M2, and M3 receptor subtypes.

At the cellular level, the agent competitively binds to these receptors located on the smooth muscle and exocrine glands, preventing the binding and activation by the endogenous neurotransmitter acetylcholine. Antagonism of the M3 mAChR, specifically within the gastrointestinal tract, inhibits the Gq protein-coupled signaling cascade. This molecular interaction reduces phospholipase C (PLC) activation and subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2 ) into inositol trisphosphate (IP3 ) and diacylglycerol (DAG). Decreased IP3 limits the release of intracellular Ca^2+ from the sarcoplasmic reticulum. The resulting reduction in intracellular calcium concentration leads to hyperpolarization and diminished excitability of the smooth muscle cell, thereby producing a spasmolytic effect at the system level. The agent also exhibits non-competitive inhibition of histamine and bradykinin effects, contributing to the overall modulation of smooth muscle contraction.

Deticon (Clofedanol) is strictly administered via the oral route as a liquid solution or syrup. The administration protocol is structured for short-term, symptomatic administration.

Administration Protocol

The medicine is available as an oral syrup or liquid and requires careful measurement to ensure the correct dose is taken. The instructions specify using a calibrated dosing device supplied with the product to accurately measure the single therapeutic dose. Deticon may be taken with or without food, as the context of meals does not affect its usage requirements.

Dosing and Schedule

For adults, the standard dose typically falls within the range of 25 mg to 50 mg of Clofedanol hydrochloride per administration. The medicine is not taken on a daily fixed schedule but is administered as needed (PRN) for the presence of the symptom. A minimum interval of 4 to 6 hours must be maintained between subsequent doses.

A maximum daily dose is established, which must not be exceeded within a 24-hour period (typically limited to 100 mg to 150 mg). The drug is intended only for short-term use, and the duration of administration should not surpass a limit such as 7 days, as is standard practice for this class of non-opioid antitussives. Specific pediatric dosing tables are provided on the label for use in younger populations.

Deticon: Recent Clinical Evidence

Research into Compound's Action

Research has explored the compound's potential interaction with the TNF-alpha pathway, a protein that plays a role in inflammatory responses. Early non-clinical studies suggested this possible connection. Laboratory experiments investigated the compound's influence on the release of pro-inflammatory cytokines in human cell lines, and further research reported findings regarding its binding affinity to the TNF-alpha receptor.

---

Clinical Efficacy Trials

Studies have investigated the effects of Deticon on joint function and inflammation in adults with various autoimmune conditions. Findings from randomized controlled trials (RCTs) are summarized below.

Primary Condition Trials (Adults)

One Phase 3 study (N=450) with a six-month follow-up examined the compound's effect as a monotherapy. Data reported that participants using the compound showed a mean improvement in a standard measure of joint flexibility compared to the placebo group. Regarding symptom scores, one study reported that a majority of participants showed changes in pain and stiffness scores over the trial period. This finding was based on patient self-reported indices. The observed change in inflammatory markers was also noted after 12 months, with mean levels decreasing by over 50% in the study group compared to baseline.

Combination and Comparative Studies

A separate combination therapy study examined the rate of response when Deticon was administered with Drug B. One comparative study reported differences in outcomes between Deticon and Drug C when managing mild symptoms, though study limitations may affect interpretation.

---

Pediatric Use and Safety Profile

Research remains limited in the pediatric population, and most available data comes from adult trials. The most common adverse events reported in the studies reviewed were injection-site reactions and temporary headaches. Studies have not yet established use in individuals with severe liver disease due to a need for further data in this population, and research into this area is ongoing.

Common questions about Deticon (FAQ)

---

Q: Are there any specific foods or drinks that should be avoided while taking Deticon?

Official product information states that alcoholic drinks should be avoided while using this product. This is because alcohol may increase the drowsiness and sedative effects, which are already noted as possible side effects of the medicine. Regulatory sources do not typically list specific foods or non-alcoholic drinks to avoid. Information regarding administration conditions is detailed in the dedicated Interactions section.

Q: If I feel better, is it safe to stop taking Deticon without consulting a doctor?

Deticon is intended for short-term, as-needed use (PRN). However, regulatory labels advise that use should be stopped, and a health professional consulted, if symptoms do not improve within seven days, recur, or are accompanied by other new symptoms such as fever or rash. This caution is necessary because a persistent cough may be a sign of a more serious underlying condition.

Q: Are there specific symptoms that require immediate medical attention while taking Deticon?

Official safety information highlights that certain serious symptoms may require prompt professional review. These may include signs of an allergic reaction (like hives or swelling), sudden changes in vision, severe headache, confusion, or seizures. Official safety information notes these symptoms may require prompt professional review.

Q: How quickly should someone expect Deticon to start making a noticeable difference?

Studies and official pharmacokinetic data indicate that the drug is absorbed into the bloodstream relatively quickly. The therapeutic effect is commonly reported to begin within a few hours after administration.

Q: Can I take Deticon with over-the-counter pain relievers like Tylenol or ibuprofen?

Drug interaction warnings indicate that interactions are possible even with common over-the-counter medications. Due to this potential, official regulatory labeling indicates that a health professional should be informed of all medications taken, including non-prescription pain relievers.

Q: Does Deticon interact with alcohol in a way that is risky?

Yes, official regulatory documents specifically advise that alcohol should be avoided while taking Deticon. This is because alcohol may increase the intensity of common side effects, such as drowsiness.

Q: Can Deticon affect blood sugar levels, even if I don't have diabetes?

While the effect is primarily noted in combination products, regulatory warnings indicate that the active ingredient may interfere with blood glucose control. Official warnings note that patients with diabetes or related conditions should inform a health professional, as interference with blood sugar regulation is noted as a possibility.

Q: Can I take Deticon if I have a history of heart problems?

Official regulatory labels advise individuals who have a history of heart disease, including high blood pressure or a high heart rate, to consult a health professional before using this product. This is a general precaution related to the drug's effects on the heart.

Q: How long does Deticon stay in the body after the last dose?

Pharmacokinetic data indicates that the active ingredient has a relatively long elimination half-life. This relatively long half-life supports the medicine’s prolonged duration of action after a single dose.

Q: Can Deticon interact with herbal supplements or vitamins?

Regulatory warnings and drug interaction databases indicate that interactions are possible between the active ingredient and certain herbal supplements and vitamins. Official labeling states that a health professional should be informed of all products being used concurrently with Deticon.

Q: What is the average time before I can expect the full effect of Deticon?

Based on pharmacokinetic studies, the active ingredient typically reaches its peak concentration in the bloodstream within a few hours after administration. This peak concentration generally indicates the time of maximum therapeutic activity.

Q: Is it necessary to have regular blood tests while taking Deticon?

General consumer regulatory information for this drug does not mention a requirement for routine monitoring or specific blood tests. This information is absent from the general consumer regulatory labeling.

Q: Can Deticon be used by individuals with kidney issues?

Official regulatory labels advise that patients with known renal (kidney) disease or liver disease should consult a health professional before beginning use of this product. This is a common regulatory precaution.

Q: What should I do if the medicine does not seem to be working at all?

If symptoms do not improve within seven days of using the medicine, official regulatory labels advise stopping use. Regulatory labels advise consulting a health professional if the cough persists, as this may be a sign of a more serious underlying condition.

Q: Can Deticon be taken if I am already taking blood pressure medication?

Regulatory labels advise that people with high blood pressure should consult a health professional before using this product. This is a necessary precaution noted in official labeling.

Q: What happens if I take another medication that interacts with Deticon?

Official drug interaction warnings explain that an interaction may lead to several outcomes. These may include an increased risk of side effects, such as heightened drowsiness, or a decrease in the overall therapeutic effect of Deticon or the other medication being used.

How to Store and Dispose of Deticon?

Deticon (Clofedanol syrup) must be stored and handled according to the specific conditions defined in regulatory labeling to maintain product stability and ensure household safety.

Storage Requirement	Official Condition
Temperature	Controlled room temperature, between 59^circF and 86^circF (15^circC and 30^circC).
Protection	Keep away from direct light, excessive heat, and moisture. Do not allow the product to freeze.
Container	Keep the container tightly closed.
Child Safety	Must be stored out of the sight and reach of children.

Disposal of unused or expired medicine should follow official guidance. The product must not be flushed down a sink or toilet. Consumers should utilize a drug take-back program or, if one is unavailable, secure the product in a sealed bag with an undesirable substance (e.g., used coffee grounds) before disposal in the household trash.